908 Devices (NASDAQ:MASS) Posts Earnings Results, Beats Expectations By $0.04 EPS

908 Devices (NASDAQ:MASS) issued its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04, FiscalAI reports. 908 Devices had a negative return on equity of 11.76% and a negative net margin of 36.87%. The firm had revenue of $18.95 million for the quarter, compared to analyst estimates of $18.31 million.

Here are the key takeaways from 908 Devices’ conference call:

• Revenue growth accelerated and guidance increased: Q3 revenue rose 35% year over year to a record $19 million, and the company raised the low end of its 2026 revenue outlook to $68.5 million–$70 million, implying 22%–25% annual growth.
• Device adoption broadened, including internationally: 908 Devices shipped a record 300-plus devices, bringing its installed base to about 4,400; international customers accounted for 40% of Q3 revenue, supported by ProtectIR government wins and other platform demand.
• NIRLab showed early commercial traction: The company sold about 100 devices in the quarter, while platform scans surpassed 1 million cumulatively. Management sees subscriptions and broader connected services as a potential source of recurring revenue, though the business is still developing.
• Profitability improved modestly, while future growth depends on execution: Adjusted EBITDA loss was $1.7 million, and the company ended Q3 with $99.1 million in cash and no debt. Management cited the next-generation MX908 and potential 2027 AVCAD orders as growth drivers, but AVCAD revenue is excluded from 2026 guidance and reaching the upper end of the outlook depends on closing key Q4 opportunities.

908 Devices Stock Performance

MASS stock opened at $10.06 on Thursday. 908 Devices has a fifty-two week low of $5.03 and a fifty-two week high of $13.35. The company has a market capitalization of $415.82 million, a price-to-earnings ratio of -15.48 and a beta of 0.66. The business’s 50 day moving average price is $11.18 and its two-hundred day moving average price is $8.53.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Stifel Nicolaus raised their price target on 908 Devices from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen downgraded shares of 908 Devices from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a report on Wednesday, November 4th. Roth Capital upped their price objective on shares of 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Canaccord Genuity Group raised their target price on shares of 908 Devices from $13.50 to $14.00 and gave the stock a “buy” rating in a research report on Thursday. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $13.67.

Insider Activity

In related news, SVP John Kenneweg sold 21,399 shares of 908 Devices stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $10.11, for a total transaction of $216,343.89. Following the sale, the senior vice president directly owned 57,784 shares in the company, valued at $584,196.24. The trade was a 27.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Joseph Griffith, IV sold 11,459 shares of 908 Devices stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $10.95, for a total value of $125,476.05. Following the sale, the chief financial officer owned 121,497 shares in the company, valued at $1,330,392.15. This represents a 8.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 134,115 shares of company stock worth $1,473,296 in the last quarter. 28.20% of the stock is owned by company insiders.

About 908 Devices

908 Devices, Inc. develops analytical instruments that help users identify and measure chemicals and biomolecules. Its products use mass spectrometry and related technologies to bring laboratory-style analysis to settings where rapid results are needed. The company’s portfolio includes handheld devices for detecting and identifying chemical substances, as well as laboratory instruments and tools used in areas such as biopharmaceutical research and protein analysis. Its customers include organizations in public safety, defense, forensics, industrial markets and life sciences.